Farah Hasan, MD
Endocrinology, Diabetes & Metabolism · Orland Park, ILNPI 1285665596
Payments from drug & device makers
Across 10 payments — averaging $24.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$65
- Abbott$55
- Dexcom, Inc.$29
- Medtronic$28
- Recordati_rare_diseases_inc.$27
- Sequel Med Tech, LLC$25
- plus $12 from 1 others
What the payments were for
- Food & beverage$22995%
- Education$125%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 1 | $65 |
| Abbott | 3 | $55 |
| Dexcom, Inc. | 2 | $29 |
| Medtronic | 1 | $28 |
| Recordati_rare_diseases_inc. | 1 | $27 |
| Sequel Med Tech, LLC | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$241 in reported general payments places this provider in the 25th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 166 | $238,393 |
| TrulicityDulaglutide | 73 | $92,731 |
| JardianceEmpagliflozin | 51 | $64,168 |
| MounjaroTirzepatide | 53 | $53,530 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $24,779 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 84 | $17,635 |
| FarxigaDapagliflozin Propanediol | 15 | $15,180 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 25 | $15,080 |
| Humalog Kwikpen U-100Insulin Lispro | 32 | $14,173 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $11,450 |
| RybelsusSemaglutide | 12 | $11,269 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 14 | $11,120 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 77 | $7,428 |
| Novolog FlexpenInsulin Aspart | 16 | $6,015 |
| Levothyroxine Sodium | 361 | $3,609 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Orland Park
- Liana BillingsSkokie$3.4M
- Leon FogelfeldChicago$1.5M
- Grazia AleppoChicago$1.4M
- Wahid KassarChicago$884K
- Anthony PickLake Forest$665K
- Hiralal MaheshwariMcHenry$642K
- Wenyu HuangChicago$639K
- Babak PazookiJoliet$582K
- Silvana PannainChicago$575K
- Ammar BayrakdarEvergreen Park$517K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.